Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2014, Article ID 269359, 3 pages
http://dx.doi.org/10.1155/2014/269359
Case Report

High-Dose Methotrexate for the Treatment of Relapsed Central Nervous System Erdheim-Chester Disease

Department of Clinical Haematology, Austin Health, Heidelberg, VIC, Australia

Received 24 March 2014; Accepted 9 June 2014; Published 16 June 2014

Academic Editor: Yoshihiro Matsukawa

Copyright © 2014 Prahlad Ho and Carole Smith. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Veyssier-Belot, P. Cacoub, D. Caparros-Lefebvre et al., “Erdheim-Chester disease: clinical and radiologic characteristics of 59 cases,” Medicine, vol. 75, no. 3, pp. 157–169, 1996. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Haroche, Z. Amoura, E. Dion et al., “Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review,” Medicine, vol. 83, no. 6, pp. 371–392, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Arnaud, B. Hervier, A. Neel et al., “CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients,” Blood, vol. 117, no. 10, pp. 2778–2782, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Haroche, F. Charlotte, L. Arnaud et al., “High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses,” Blood, vol. 120, no. 13, pp. 2700–2703, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Babu, T. Lansen, A. Chadburn, and S. Kasoff, “Erdheim-Chester disease of the central nervous system: report of two cases,” Journal of Neurosurgery, vol. 86, no. 5, pp. 888–892, 1997. View at Google Scholar · View at Scopus
  6. C. Myra, L. Sloper, P. J. Tighe et al., “Treatment of Erdheim-Chester disease with cladribine: a rational approach,” British Journal of Ophthalmology, vol. 88, no. 6, pp. 844–847, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Perry, The Chemotherapy Source Book, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 4th edition.
  8. J. Haroche, F. Cohen-Aubart, J.-F. Emile et al., “Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation,” Blood, vol. 121, no. 9, pp. 1495–1500, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. Therapeutic Goods Administration and Australian Government, “Australian Public Assessment Report for Vemurafenib,” http://www.tga.gov.au/pdf/auspar/auspar-vemurafenib-121217.pdf.